(Q24245681)

3

0 references

author name string

Clare Donnellan

1

0 references

Cathy Preston

2

0 references

Nav Sharma

Cochrane Database of Systematic Reviews

4

0 references

publication date

18 October 2004

0 references

published in

0 references

cites work

Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Prevention of Relapse of Reflux Esophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with Ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Maintenance therapy with cisapride after healing of erosive oesophagitis: a double‐blind placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Healing and prevention of relapse of reflux oesophagitis by cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Ranitidine in reflux oesophagitis. A double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Combination therapy of sucralfate and cimetidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Long-term treatment of erosive esophagitis with omeprazole: does it work?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Two-year follow-up after one year's treatment with cimetidine or placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Histamine H2 antagonists in acute upper gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

A comparison of five maintenance therapies for reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Long-term therapy for reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Effects of long-term medical treatment with cimetidine and bethanechol in patients with esophagitis and Barrett's esophagus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Relapse rate of patients after healing of oesophagitis--a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Cimetidine and metoclopramide in oesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

An evidence-based appraisal of reflux disease management--the Genval Workshop Report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Metoclopramide in the treatment of reflux oesophagitis: a comparison of normal and controlled-release formulations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Gastroesophageal reflux disease. Acute and maintenance treatments with cimetidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003245.PUB2

7 January 2021

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease.

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003245.PUB2

A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials

9 February 2024

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003245.PUB2

Cimetidine in the treatment of reflux oesophagitis

9 February 2024

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003245.PUB2